{
  "run_id": "c04529d5-de26-4fcb-9c95-622edc68cf5d",
  "prompt_variant_id": "ab5f4aab-df30-44a2-8395-d1bf33b1ad94",
  "api_config_name": "model_gpt_4o",
  "test_case_id": "breast_cancer_her2_positive",
  "start_time": "2025-09-01T16:18:24.926612",
  "end_time": "2025-09-01T16:18:27.474490",
  "duration_ms": 2541.7847633361816,
  "success": true,
  "error_message": "",
  "entities_extracted": 15,
  "entities_mapped": 8,
  "extraction_completeness": 0.9375,
  "mapping_accuracy": 0.6666666666666665,
  "precision": 0.8125,
  "recall": 0.8125,
  "f1_score": 0.8125,
  "compliance_score": 1.0,
  "token_usage": 3273,
  "extracted_entities": [
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.95,
      "source_context": {
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.95,
      "source_context": {
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.95,
      "source_context": {
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Measurable disease per RECIST 1.1",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.9,
      "source_context": {
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "ECOG performance status 0-1",
      "type": "demographic",
      "attributes": {
        "status": "positive",
        "value": "0-1",
        "unit": null
      },
      "confidence": 0.92,
      "source_context": {
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Adequate organ function",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.88,
      "source_context": {
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Prior treatment with Trastuzumab Deruxtecan",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null
      },
      "confidence": 0.93,
      "source_context": {
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Active brain metastases",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null
      },
      "confidence": 0.94,
      "source_context": {
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy or breastfeeding",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null
      },
      "confidence": 0.91,
      "source_context": {
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.95,
      "source_context": {
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.9,
      "source_context": {
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "trastuzumab-based therapy",
      "type": "exclusion",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.85,
      "source_context": {
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.95,
      "source_context": {
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.95,
      "source_context": {
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.9,
      "source_context": {
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    }
  ],
  "mcode_mappings": [
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 0",
      "mapping_rationale": "The entity 'HER2-Positive Breast Cancer' directly maps to the mCODE element 'CancerCondition' as it specifies a type of cancer diagnosis.",
      "id": "dd91a9f1-0c45-4611-b5b1-3acd8d72905d",
      "llm_source_text_fragment": "Entity index 0",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic Breast Cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 1",
      "mapping_rationale": "The entity 'Metastatic Breast Cancer' is a specific cancer diagnosis and maps to 'CancerCondition'.",
      "id": "28be4738-e1ea-4c56-a5a3-c87658cd613f",
      "llm_source_text_fragment": "Entity index 1",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 2",
      "mapping_rationale": "This entity combines HER2 status and metastatic breast cancer, mapping to 'CancerCondition'.",
      "id": "b94bb471-0de4-4361-929c-c5e2cd7aa5ce",
      "llm_source_text_fragment": "Entity index 2",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "ECOGPerformanceStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "ecogperformancestatus",
        "display": "ECOGPerformanceStatus"
      },
      "value": "0-1",
      "mapping_confidence": 0.92,
      "source_text_fragment": "Entity index 4",
      "mapping_rationale": "The ECOG performance status is a standard measure of patient performance and maps to 'ECOGPerformanceStatus'.",
      "id": "d9106fcf-9617-4161-9dd2-47760b4ddd6c",
      "llm_source_text_fragment": "Entity index 4",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 0.93,
      "source_text_fragment": "Entity index 6",
      "mapping_rationale": "Trastuzumab Deruxtecan is a medication used in cancer treatment, mapping to 'CancerRelatedMedication'.",
      "id": "56d4daa4-28e9-41c0-aa8b-7639c25c5ba7",
      "llm_source_text_fragment": "Entity index 6",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 10",
      "mapping_rationale": "HER2-positive is a biomarker status, mapping to 'GenomicVariant'.",
      "id": "fac5cedb-b721-45be-835c-12f5cf81223d",
      "llm_source_text_fragment": "Entity index 10",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "trastuzumab",
      "mapping_confidence": 0.85,
      "source_text_fragment": "Entity index 12",
      "mapping_rationale": "Trastuzumab is a standard HER2-targeted therapy, mapping to 'CancerRelatedMedication'.",
      "id": "05bfe887-4cda-4dd6-a66c-da9169345f6c",
      "llm_source_text_fragment": "Entity index 12",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-Positive",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 14",
      "mapping_rationale": "HER2-Positive is a biomarker status, mapping to 'GenomicVariant'.",
      "id": "da625647-d185-44ce-9609-d93b310f306a",
      "llm_source_text_fragment": "Entity index 14",
      "source_references": []
    }
  ],
  "validation_results": {
    "valid": true,
    "errors": [],
    "warnings": [],
    "compliance_score": 1.0
  }
}